PMID- 27238400
OWN - NLM
STAT- MEDLINE
DCOM- 20170712
LR  - 20181202
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 16
IP  - 9
DP  - 2016 Sep
TI  - Progress of dendritic cell-based cancer vaccines for patients with hematological 
      malignancies.
PG  - 1113-23
LID - 10.1080/14712598.2016.1196181 [doi]
AB  - INTRODUCTION: Dendritic cells (DCs) are the most professional antigen-presenting 
      cells eliciting cellular and humoral immune responses against cancer cells by 
      expressing these antigens on MHC class I/II complexes to T cells. Therefore, they 
      have been employed in many clinical trials as cancer vaccines for patients with 
      cancer. This review focuses on the use of DCs in leukemia patients expressing 
      leukemia-associated antigens (LAAs). AREAS COVERED: The contribution of both 
      stimulating vs. tolerogenic DCs as well as of other factors to the milieu of 
      anti-leukemia immune responses are discussed. Several DC vaccination strategies 
      like leukemia lysate, proteins and peptides have been developed. Next generation 
      DC vaccines comprise transduction of DCs with retroviral vectors encoding for 
      LAAs, cytokines and costimulatory molecules as well as transfection of DCs with 
      naked RNA encoding for LAAs. Published as well as ongoing clinical trials are 
      reported and critically reviewed. EXPERT OPINION: Future results will demonstrate 
      whether next-generation DCs are really superior to conventional pulsing with 
      peptide, protein or tumor lysate. However, currently available methods based on 
      nucleic acid transfection/transduction are tempting in terms of material 
      production costs and time for clinical application according to good 
      manufacturing practice (GMP).
FAU - Ni, Ming
AU  - Ni M
AD  - a Cellular Immunotherapy, GMP Core Facility, Department of Internal Medicine V , 
      Heidelberg University Hospital , Heidelberg , Germany.
FAU - Hoffmann, Jean-Marc
AU  - Hoffmann JM
AD  - a Cellular Immunotherapy, GMP Core Facility, Department of Internal Medicine V , 
      Heidelberg University Hospital , Heidelberg , Germany.
FAU - Schmitt, Michael
AU  - Schmitt M
AD  - a Cellular Immunotherapy, GMP Core Facility, Department of Internal Medicine V , 
      Heidelberg University Hospital , Heidelberg , Germany.
FAU - Schmitt, Anita
AU  - Schmitt A
AD  - a Cellular Immunotherapy, GMP Core Facility, Department of Internal Medicine V , 
      Heidelberg University Hospital , Heidelberg , Germany.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160609
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/biosynthesis/immunology
MH  - Cancer Vaccines/immunology/*therapeutic use
MH  - Dendritic Cells/*immunology/metabolism/*transplantation
MH  - Hematologic Neoplasms/*immunology/metabolism/*therapy
MH  - Humans
MH  - T-Lymphocytes/drug effects/immunology/metabolism
MH  - Vaccination/methods
OTO - NOTNLM
OT  - Dendritic cells (DCs)
OT  - cancer antigens
OT  - cancer vaccines
OT  - gene transfer
OT  - leukemia
EDAT- 2016/05/31 06:00
MHDA- 2017/07/14 06:00
CRDT- 2016/05/31 06:00
PHST- 2016/05/31 06:00 [entrez]
PHST- 2016/05/31 06:00 [pubmed]
PHST- 2017/07/14 06:00 [medline]
AID - 10.1080/14712598.2016.1196181 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2016 Sep;16(9):1113-23. doi: 
      10.1080/14712598.2016.1196181. Epub 2016 Jun 9.